Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q3 2019 · 10-Q
Revenue$184.00K$184.00Kno prior Q3 2018 on file Net Income-$5.65M-$5.65MN/M vs Q3 2018 EPS Diluted-$1.47-$1.47N/M vs Q3 2018 Operating Income-$5,498,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,281,000N/M Margins · derivedOperating margin-2988.0%
Net margin-3067.9%
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end